: Drug repurposing is an ongoing and clever strategy that is being developed to eradicate tuberculosis amid challenges, of which one of the major challenges is the resistance developed towards antibiotics used in standard directly observed treatment, short-course regimen. Surpassing the challenges in developing anti-tuberculous drugs, some novel host-directed therapies, repurposed drugs, and drugs with novel targets are being studied, and few are being approved too. After almost 4 decades since the approval of rifampicin as a potent drug for drugsusceptible tuberculosis, the first drug to be approved for drug-resistant tuberculosis is bedaquiline. Ever since the urge to drug discovery has been at a brisk as this milestone in tuberculosis treatment has provoked the hunt for novel targets in tuberculosis. Host-directed therapy and repurposed drugs are in trend as their pharmacological and toxicological properties have already been researched for some other diseases making the trial facile. This review discusses the remonstrance faced by researchers in developing a drug candidate with a novel target, the furtherance in tuberculosis research, novel anti-tuberculosis agents approved so far, and candidates on trial including the host-directed therapy, repurposed drug and drug combinations that may prove to be potential in treating tuberculosis soon, aiming to augment the awareness in this context to the imminent researchers.

中文翻译：

---

营养保健品通​​过抑制磷酸二酯酶 5 酶治疗勃起功能障碍的作用：小综述

：药物再利用是一项持续而明智的策略，正在开发中，以在挑战中根除结核病，其中主要挑战之一是对标准直接观察治疗、短期治疗方案中使用的抗生素产生的耐药性。克服开发抗结核药物的挑战，一些新型宿主导向疗法、重新利用药物和具有新靶点的药物正在研究中，但获得批准的药物也很少。自利福平被批准作为治疗药物敏感结核病的强效药物近 4 年后，第一个被批准用于治疗耐药结核病的药物是贝达喹啉。从那时起，对药物发现的渴望就一直很旺盛，因为结核病治疗的这一里程碑引发了对结核病新靶标的寻找。宿主导向治疗和重新利用药物已成为趋势，因为它们的药理学和毒理学特性已经针对其他一些疾病进行了研究，使得试验变得容易。这篇综述讨论了研究人员在开发具有新靶点的候选药物时面临的抗议、结核病研究的进展、迄今为止批准的新型抗结核药物以及正在试验的候选药物，包括宿主导向疗法、重新利用的药物和药物组合可能很快就会被证明具有治疗结核病的潜力，旨在提高即将到来的研究人员在这方面的认识。